Global Fairness in Drug Pricing Act
Sponsored By: Representative Khanna
Introduced
Summary
This bill would lower U.S. prescription drug costs by making U.S. prices more like prices in comparably developed countries. It pairs most-favored-nation price targets with selective importation and stronger antitrust tools to push down manufacturer prices.
Show full summary
- Families and patients: Would aim to make what Americans pay for prescription drugs comparable to prices in similarly developed countries. It also directs HHS to describe when individuals can get case-by-case waivers to import drugs from low-cost developed countries and to certify that importation would be safe and significantly reduce costs.
- Pharmaceutical manufacturers: Would authorize enforcement actions by the Attorney General and the Federal Trade Commission Chair under sections 1 and 2 of the Sherman Act and section 5 of the FTC Act against anticompetitive conduct by manufacturers.
- Federal agencies and trade policy: Would require HHS to coordinate with CMS and other agencies to propose a rulemaking plan within 30 days after enactment to set most-favored-nation price targets, direct HHS to facilitate direct-to-consumer purchasing at those prices when legal, and ask Commerce and the U.S. Trade Representative to study manufacturer conduct with findings due to Congress within 180 days.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Crack down on drug-maker collusion
The Justice Department and the FTC would target anti-competitive practices by drug makers, as allowed by law. They could use laws against price-fixing and monopolies. Stronger enforcement could help keep drug prices fair for many households.
Allow safe personal drug importation
HHS would need to certify to Congress that personal drug importation is safe and would significantly cut costs. HHS would explain when individuals could get case-by-case waivers to import from developed countries with lower prices. Only people who meet those rules could import. If approved, some patients could buy cheaper medicines from abroad.
Global benchmarks for U.S. drug prices
Within 30 days of enactment, HHS would propose a plan to set most-favored-nation price targets so U.S. patients pay prices similar to those in other developed countries. HHS would coordinate with Medicare, Medicaid, and other agencies. HHS could also help drug makers sell directly to patients at those benchmark prices, where allowed by law. This is a first step; any price limits would come later through rules.
Sponsors & CoSponsors
Sponsor
Khanna
CA • D
Cosponsors
Luna
FL • R
Sponsored 5/19/2025
Kaptur
OH • D
Sponsored 5/19/2025
Biggs (AZ)
AZ • R
Sponsored 5/19/2025
Crane
AZ • R
Sponsored 6/3/2025
Greene (GA)
GA • R
Sponsored 10/17/2025
Subramanyam
VA • D
Sponsored 11/7/2025
Barrett
MI • R
Sponsored 2/24/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in